May is Mental Health Awareness Month—a time to recognize the importance of emotional well-being at every stage of life.
Mental health and Alzheimer’s disease are deeply connected. That’s why early detection, clinical research, and open conversations matter.

#MentalHealthAwarenessMonth

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

Click the link for full interview: acumenpharm.com/ask-acumen/

#AskAcumen #PeopleFirst #EmployeeSpotlight

As #AAN2025 comes to an end we’d like to thank the American Academy of Neurology for another meaningful meeting -- and for highlighting the latest in #Alzheimers research.

We were honored to present and look forward to attending next year!

Earlier today Elizabeth Johnson, PhD, presented a poster at the @aanmember.bsky.social conference in San Diego.

🔗See the full poster here along with our other presentations: acumenpharm.com/document-lib...

#AAN25 #AAN2025 #AANAM

Yesterday at the American Academy of Neurology annual conference we presented advancements in trial screening for ALTITUDE-AD, our Phase 2 study of sabirnetug targeting early #AlzheimersDisease.

#AAN25 #AANAM #AAN202

🔗Click to see the full presentation: acumenpharm.com/document-lib...

All good things must come to an end -- and while the Acumen team is sad to leave the #ADPD2025 Conference, it’s been a wonderful week of sharing knowledge and innovation in the #Alzheimer’s field. We’ll see you all next year!

Putting the spotlight on our #ADPD2025 posters today! Elizabeth Johnson presented a poster titled “Utility of Human iPSC-derived Neuronal Model for Evaluating Synaptic Binding of Aβ Oligomers”

🔗See the full poster here along with our other presentations:
acumenpharm.com/document-lib...

Putting the spotlight on our #ADPD2025 posters today! Erika Cline, PhD presented a poster titled “Preparing Stable Monomeric Aβ to Assess AβO Selectivity Assays”

🔗 See the full poster here along with our other presentations:
acumenpharm.com/document-lib...

Yesterday our CMO Eric Siemers MD presented at #ADPD2025 on the use of a pTau217 assay for screening participants in our ongoing phase 2 study, ALTITUDE-AD. Stay tuned for more updates on our upcoming conference activities.

Click for more: lnkd.in/gvhaCFBV

We’re excited to be presenting at AD/PD - Advances in Science & Therapy 2025 this week! Whether you’re joining live in Vienna or catching it virtually, check out our presentation, posters and a forum with our CMO Dr. Eric Siemers.

#Alzheiemrs #ADPD #ADPD2025

Yesterday we announced our Full Year 2024 financial results and business highlights.

🔗 Click link to read the release: investors.acumenpharm.com/news-release...

#BreakingNews We have completed enrollment in our Phase 2 ALTITUDE-AD trial of sabirnetug ahead of schedule with topline results expected late 2026! Thanks to all the participants, investigators and our amazing team.

Learn more: investors.acumenpharm.com/news-release...

#Alzheimers #ALZ

Congrats to our research team and co-authors who recently published results of biomarker analysis from our Phase 1 INTERCEPT-AD study in The Journal of Prevention of Alzheimer's Disease (JPAD)

🔗Link: doi.org/10.1016/j.tj...

#Alz #AlzheimersDisease #Alzheimers #biomarkers

This week our CMO Eric Siemers MD presented at the 13th Alzheimer’s and Parkinson’s Drug Development Summit in Boston.

View the full presentation here: acumenpharm.com/document-lib...

#apdd #drugdevelopment #apdd2025

Today we shared topline results from our Phase 1 study of the subcutaneous formulation of sabirnetug. Administrations were well-tolerated with systemic exposure supporting further clinical development.

Learn more about the results: tinyurl.com/fkuevuhv

#Alzheimers #Alz

We’re attending #ADPD2025 and #AAN2025 to share findings supporting our comprehensive development program for sabirnetug, including a pTau217 assay for participant screening in our Phase 2 study!

🔗Save the dates and learn more: tinyurl.com/3rjxjhjk

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

🔗Click the link to read the interview: acumenpharm.com/ask-acumen/

#AskAcumen #EmployeeSpotlight